Bone Biologics Corp
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
BBLG$0.34+3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets
| June 30, 2026 | December 31, 2025 | |
|---|---|---|
| (unaudited) | ||
| Assets | ||
| Current Assets | ||
| Cash | $4,031,780 | $5,334,322 |
| Advances on research and development contract services | 208,972 | 208,972 |
| Prepaid insurance | 126,264 | 232,946 |
| Prepaid financing costs | 52,666 | - |
| Interest Receivable | 6,986 | 9,895 |
| Prepaid expenses | 10,000 | 10,000 |
| Total current assets | 4,436,668 | 5,796,135 |
| Total assets | $4,436,668 | $5,796,135 |
| Liabilities and Stockholders’ Equity | ||
| Current Liabilities | ||
| Accounts payable and accrued expenses | $511,472 | $417,884 |
| Warrant liability | 546 | 703 |
| Total current liabilities | 512,018 | 418,587 |
| Total liabilities | 512,018 | 418,587 |
| Commitments and Contingencies | - | - |
| Stockholders’ Equity | ||
| Preferred Stock, $0.001 par value per share; 20,000,000 shares authorized; none issued or outstanding at June 30, 2026 and December 31, 2025 | - | - |
| Common stock, $0.001 par value per share; 100,000,000 shares authorized; 1,810,380 and 1,795,260 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | 1,810 | 1,795 |
| Additional paid-in capital | 93,592,899 | 93,506,122 |
| Accumulated deficit | (89,670,059) | (88,130,369) |
| Total stockholders’ equity | 3,924,650 | 5,377,548 |
| Total liabilities and stockholders’ equity | $4,436,668 | $5,796,135 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.